TITLE

Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry

AUTHOR(S)
Penz, Sandra M.; Bernlochner, Isabell; Tóth, Orsolya; Lorenz, Reinhard; Calatzis, Andreas; Siess, Wolfgang
PUB. DATE
January 2010
SOURCE
Thrombosis Journal;2010, Vol. 8, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Poor platelet inhibition by aspirin or clopidogrel has been associated with adverse outcomes in patients with cardiovascular diseases. A reliable and facile assay to measure platelet inhibition after treatment with aspirin and a P2Y12 antagonist is lacking. Multiple electrode aggregometry (MEA), which is being increasingly used in clinical studies, is sensitive to platelet inhibition by aspirin and clopidogrel, but a critical evaluation of MEA monitoring of dual antiplatelet therapy with aspirin and P2Y12 antagonists is missing. Design and Methods: By performing in vitro and ex vivo experiments, we evaluated in healthy subjects the feasibility of using MEA to monitor platelet inhibition of P2Y12 antagonists (clopidogrel in vivo, cangrelor in vitro) and aspirin (100 mg per day in vivo, and 1 mM or 5.4 mM in vitro) alone, and in combination. Statistical analyses were performed by the Mann-Whitney rank sum test, student' t-test, analysis of variance followed by the Holm-Sidak test, where appropriate. Results: ADP-induced platelet aggregation in hirudin-anticoagulated blood was inhibited by 99.3 ± 1.4% by in vitro addition of cangrelor (100 nM; p < 0.001) and by 64 ± 35% by oral clopidogrel (600 mg) intake (p < 0.05; values are means ± SD). Pre-incubation of blood with aspirin (1 mM) or oral aspirin intake (100 mg/day for 1 week) inhibited arachidonic acid (AA)-stimulated aggregation >95% and 100 ± 3.2%, respectively (p < 0.01). Aspirin did not influence ADP-induced platelet aggregation, either in vitro or ex vivo. Oral intake of clopidogrel did not significantly reduce AA-induced aggregation, but P2Y12 blockade by cangrelor (100 nM) in vitro diminished AA-stimulated aggregation by 53 ± 26% (p < 0.01). A feasibility study in healthy volunteers showed that dual anti-platelet drug intake (aspirin and clopidogrel) could be selectively monitored by MEA. Conclusions: Selective platelet inhibition by aspirin and P2Y12 antagonists alone and in combination can be rapidly measured by MEA. We suggest that dual anti-platelet therapy with these two types of anti-platelet drugs can be optimized individually by measuring platelet responsiveness to ADP and AA with MEA before and after drug intake.
ACCESSION #
51157905

 

Related Articles

  • URINARY 11-DEHYDRO-THROMBOXANE B2 AS A MARKER OF THE ANTI-PLATELET EFFECTS OF CLOPIDOGREL OR ASPIRIN THERAPY IN HEALTHY MALE VOLUNTEERS. Armstrong, P. C. J.; Dhanji, A. A.; Tucker, A. T.; Mitchell, J. A.; Warner., T. D. // Heart;Nov2009, Vol. 95 Issue 22, p1 

    Activated platelets release large amounts of the cyclooxygenase-dependent product, thromboxane A2 (TxA2), and increased urinary levels of the TxA2 metabolite 11-dehydro-thromboxane B2 (Tx-M) appear positively associated with atherosclerotic disease (1,2). Anti-thrombotic doses of aspirin...

  • Antiplatelet therapy in cardiovascular disease. Behan M W H; Storey R F // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p155 

    Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and...

  • QUANTIFICATION OF 11-DEHYDRO-THROMBOXANE B2 IN URINE - ADVISABLE LABORATORY METHOD FOR DETECTION ASPIRIN EFFICACY OR RESISTANCE? DANIELA, KOTULICOVA; JELA, IVANKOVA; PETER, CHUDY; MIROSLAVA, DOBROTOVA; JAN, STAŠKO; PETER, KUBISZ // Acta Medica Martiniana;Jul2009, Vol. 9 Issue 2, p3 

    Increased incidence of cardiovascular events in patients with the insufficient inhibition of platelet function tests has been shown in many studies. Therefore, identification of patients with high residual platelet reactivity, despite of receiving aspirin in long-term prevention may be useful to...

  • Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Rossini, Roberta; Musumeci, Giuseppe; Nijaradze, Tamar; Gavazzi, Antonello // Clinical Medicine: Therapeutics;2009, Issue 1, p899 

    Antiplatelet therapy is the cornerstone in the modern therapy of patients with acute coronary syndromes (ACS), because of the unique role of platelets in coronary thrombosis. Clopidogrel in combination with aspirin is the current "gold standard" for reducing cardiovascular events in such...

  • Low phospholipid arachidonic acid values in diabetic platelets. Jones, D.B.; Carter, R.D.; Haitas, B.; Mann, J.I. // British Medical Journal (Clinical Research Edition);1/15/1983, Vol. 286 Issue 6360, p173 

    Measures low phospholipid arachidonic acid in diabetic platelets. Correlation between percentages of arachidonic acid and glycosylated hemoglobin; Determination of the fatty acid composition of platelet phospholipid; Description of abnormal platelet aggregation.

  • Antiplatelet therapy in cardiovascular disease. Behan M W H; Storey R F // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p155 

    Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and...

  • Antithrombotic effects of aspirin may not be irreversible. Raible, Eric // Cardiology Today;Feb2008, Vol. 11 Issue 2, p5 

    The article focuses on the effect of aspirin in antiplatelet and antithrombotic therapy. In a randomized trial of patients assigned 150 mg of aspirin before surgery, researchers identified an increase in aggregation of platelets to arachidonic acid at the end of the operation even though the...

  • Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Hansson, E. C.; Shams Hakimi, C.; Åström-Olsson, K.; Hesse, C.; Wallén, H.; Dellborg, M.; Albertsson, P.; Jeppsson, A. // BJA: The British Journal of Anaesthesia;Mar2014, Vol. 112 Issue 3, p570 

    Background Transfusion of platelet concentrate is often used to treat bleeding in patients on platelet inhibitors, but little is known about its efficacy between different inhibitors. We assessed the effect of ex vivo platelet supplementation on platelet aggregability in blood samples from...

  • Attenuation of Thrombosis by Crude Rice (Oryza sativa) Bran Policosanol Extract: Ex Vivo Platelet Aggregation and Serum Levels of Arachidonic Acid Metabolites. Wong, Wai-Teng; Ismail, Maznah; Tohit, Eusni Rahayu Mohd; Abdullah, Rasedee; Zhang, Yi-Da // Evidence-based Complementary & Alternative Medicine (eCAM);10/5/2016, p1 

    Background. Vascular occlusion or thrombosis was often attributed to uncontrolled platelet activation. Influence of sugarcane policosanol extract on platelet was reported but little was known of rice bran policosanol, particularly its mechanisms of actions on platelet activities. Objective....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics